Skip to main
PRCT

PRCT Stock Forecast & Price Target

PRCT Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 30%
Buy 50%
Hold 10%
Sell 10%
Strong Sell 0%

Bulls say

PROCEPT BioRobotics has demonstrated strong financial performance, reporting Q3’25 sales of $83.3 million, reflecting a significant year-over-year growth of 43%, which exceeded both internal targets and consensus estimates. The company is anticipating an acceleration in procedure volumes by more than 50% year-over-year during the second half of 2026, driven by effective commercial initiatives and a robust product pipeline. Additionally, the strong placement of 58 new capital systems in the quarter, surpassing previous guidance, signals increasing utilization in the urology sector, supporting sustainable double-digit growth in the company's revenue.

Bears say

PROCEPT BioRobotics Corp's forecasted financial performance has been negatively impacted by a fourth-quarter revenue that fell 19% below consensus expectations, forcing the company to meaningfully adjust its FY26 guidance downwards. The company’s anticipated sales for FY26 are projected at $390-410 million, which is 5% beneath consensus estimates, indicating challenges in both U.S. and international markets, particularly with US sales falling short by 7%. Furthermore, the reduction in handpiece sales, attributed to the cessation of bulk purchase discounts and inventory de-stocking, exacerbates the disappointing financial outlook and contributes to the significant volatility in the company's stock performance.

PRCT has been analyzed by 10 analysts, with a consensus rating of Buy. 30% of analysts recommend a Strong Buy, 50% recommend Buy, 10% suggest Holding, 10% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of PROCEPT BioRobotics Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About PROCEPT BioRobotics Corp (PRCT) Forecast

Analysts have given PRCT a Buy based on their latest research and market trends.

According to 10 analysts, PRCT has a Buy consensus rating as of Apr 22, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $37.90, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $37.90, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

PROCEPT BioRobotics Corp (PRCT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.